Kotobuki’s History

dozo1

1949
Establishment of Kotobuki Pharmaceutical.
Started to sell herbal medicines which are extracted from herbs
that are mainly produced in Nagano Prefecture. (Apricot kernel water,
Scopolia extract, Senega syrup etc.)
1959
10th anniversary of foundation.
1965
Start to develop of synthetic active pharmaceutical ingredients focused
particularly on research on manufacturing imported active pharmaceutical
ingredients domestically.
1969
20th anniversary of foundation.
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
MARZULENE-S GRANULES in Japan.
1978
Completion of pharmacy plant based on GMP (Good Manufacturing Practice).
Completion of the first stage construction of Research Laboratory.
麦滋林(中国)
麦滋林(china)
GLUTAZENE(India)
AZULOXA GRANULES(South Korea)
AZULOXA GRANULES
(South Korea)
Suglat Tablets 25mg、50mg
Suglat Tablets 25mg, 50mg
1979
30th anniversary of foundation.
1987
Completion of the second stage construction of Research Laboratory.
This leads to a start of full-scale development of new pharmaceuticals.
1989
Founding 40th anniversary commemorative magazine “Housu” published.
Completion of research facilities of Radio Isotope.
1990
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
MARZULENE-S GRANULES in China.
1993
Completion of the second pharmacy plant based on GMP.
1999
50th anniversary of foundation.
2000
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
MARZULENE-S GRANULES in India.
2001
Launched new Gastric ulcer therapeutic agent AZULOXA GRANULES
(Egualen Sodium) in Japan.
2003
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
MARZULENE ES TABLETS (Dosage form addition).
2004
Launched Gastric ulcer therapeutic agent AZULOXA GRANULES
in South Korea.
Conformed to the inspection for compliance with the GCP
(Good Clinical Practice)carried out by PMDA (Pharmaceuticals and
Medical Devices Agency).
2005
Conformed to the inspection on synthesized drug substances carried
out by foreign country regulatory authority.
2006
Conformed to the inspection on AZULOXA GRANULES for compliance
with the GPMSP (Good Post-Marketing Surveillance Practice) carried
out by PMDA.
2008
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
MARZULENE COMBINATION TABLETS 0.5ES (Dosage form addition).
2009
60th anniversary of foundation.
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
MARZULENE COMBINATION TABLETS 0.375ES (Dosage form addition).
2010
We performed an invitation lecture of cholesterol absorption
inhibitor KT6-971 by a medicinal chemistry sectional meeting of Americanization society(ACS).
2011
Gastric ulcer therapeutic agent AZULOXA TABLETS 15mg in Japan.
2012
We changed development number of cholesterol absorption inhibitor
KT6-971 to S-556971.
2013
Submits Application for Marketing Approval of Ipragliflozin /
Suglat Tablets 25mg, 50mg.
SGLT2 Inhibitor for Treatment of Type 2 Diabetes(Joint development
with Astellas Pharma Inc.), in Japan.
2014
Approval of Suglat Tablets, a Selective SGLT2 Inhibitor for Treatment
of Type 2 Diabetes(Joint development with Astellas Pharma Inc.),
acquires production sale approval in the country and is published
medicine charge. It released it.
2015
Approval of Suglat Tablets, a Selective SGLT2 Inhibitor for Treatment
of Type 2 Diabetes(Joint development with Astellas Pharma Inc.),
acquires production sale approval in Korea and is published
medicine charge. It released it.
We changed the package design and packaging materials of MARZULENE S
COMBINATION GRANULES.
Astellas Initiates Phase 3 Registration Trial of gilteritinib (ASP2215)
in Relapsed or Refractory Acute Myeloid Leukemia Patients.

President Tomiyama and chief Noda at drug research institute were awarded
at 33rd Medicinal Chemistry Symposium by the Pharmaceutical Society of Japan.
The title is “Creation of Selective SGLT2 inhibitor – novel oral hypoglycemic agent SuguraTM.
2017
Submits application for approval of type-2 diabetes drug combining selective
SGLT2 inhibitor “Suglat® Tablets” and selective DPP-4 inhibitor “JANUVIA® Tablets”
( Joint development with Astellas Pharma Inc. and MSD )
U.S. FDA Grants Orphan-Drug Designation for Development of FLT3 Inhibitor Gilteritinib
in Acute Myeloid Leukemia


2015110509sakurasakura本社屋上から観た北アルプス